Trends in the safety of high dose bolus
β
Udai S. Kammula; Donald E. White; Steven A. Rosenberg
π
Article
π
1998
π
John Wiley and Sons
π
English
β 130 KB
π 2 views
## BACKGROUND. Administration of recombinant high dose interleukin-2 (IL-2) can mediate tumor regression in patients with metastatic melanoma and renal carcinoma. Significant trends in the safety of high dose IL-2 administration at a single institution over a 12-year study period were reviewed. #